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Statistical methods necessary for clinical studies
Clinical comparative studies require randomization and 
masking. On clinically studying administration methods, it 
is difﬁ cult to perform a double-masked randomized trial. If 
double-masked testing is rarely adopted, it is desirable to 
have patients randomly allotted to groups by a controller. 
In studies to evaluate prophylactic antimicrobial drugs for 
postoperative infections, multicenter trials may be neces-
sary for the registration of the statistically necessary number 
of patients as subjects. In such situations, it is desirable to 
conduct randomized allocations at each center as a unit (for 
example, block allocation, stratiﬁ ed allocation). Multi-
institutional studies also have the advantage that the results 
allow general evaluation without center-speciﬁ c ﬁ ndings. 
On the other hand, because marked differences among 
centers in factors other than antimicrobial drugs,, including 
surgical procedures and perioperative management, can 
affect the results of a study, special attention should be paid 
to the implementation of multicenter trials.
Meta-analyses have also been performed. Metaanalysis 
requires the use of procedures such as the Mantel-Haenszel 
technique to consolidate results from a number of studies, 
taking into consideration differences in protocols.1 Because 
meta-analyses are greatly inﬂ uenced by bias (for example, 
selection bias), attention should be paid to the selection of 
the study results that are used in the analysis.
There are two comparative study patterns, one for indi-
cating superiority and the other for indicating equality or 
noninferiority. Usually, the latter type is used for the clini-
cal evaluation of AMP agents. The results are analyzed in 
all patients who are allocated to a study group (intention-
to-treat [ITT] analysis), regardless of whether or not the 
patients meet the criteria for registration as subjects (that 
is, their treatment is in accordance with the study protocol). 
It is important, for the evaluation of study quality, to 
compare the results of the analysis of only those patients 
who meet the criteria for registration as subjects, and the 
results of ITT analysis of all the patients allocated to a study 
group.
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Introduction
The objectives of preparing the guidelines are to describe 
how to implement clinical studies of antimicrobial prophy-
laxis (AMP) for postoperative infections. The guidelines 
focus speciﬁ cally not only on the evaluation of antimicro-
bial drugs themselves but also on the preparation of proto-
cols regarding usage (e.g., duration of use and timing of 
administration). The guidelines also include information 
for physician-led clinical studies, not those managed by 
pharmaceutical companies, as subjects. They scientiﬁ cally 
describe the statistical methods that can be used in clinical 
settings, including the numbers of patients for whom data 
are calculated and the methods of allocation to groups. The 
guidelines are based on clinical evidence in the present situ-
ation, and therefore, in the future, revision of the guidelines 
may need to be considered if new clinical evidence accumu-
lates in Japan.
Open access under the Elsevier OA license. 
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Number of patients required for a noninferiority study
When a noninferiority study is planned, the number of 
patients required for the study depends mainly on the pro-
spective incidence of surgical-site infection (SSI) and on the 
permissible difference in the incidence (%) that is not con-
sidered to be clinically problematic. When the incidence of 
SSI is 12% in each group and the upper limit of the 90% 
conﬁ dence interval of the between-groups difference (based 
on the SSI of the control group) is less than 5% (which is 
regarded as noninferiority), and the power of the test is 
80%, then it is assumed that 515 patients would be required 
in each group for evaluation by the statistical noninferiority 
test (one-sided signiﬁ cance level, 5%). Figure 1 shows the 
number of patients required for a study when the incidence 
of SSI in each group varies from 5% to 30%.
In the present situation, it is difﬁ cult to perform clinical 
studies involving such numbers of patients in Japan. Sup-
posing a practicable number is between 100 and 150, when 
the incidence of SSI is 6%, and the noninferiority detection 
level is 7%, then, according to the assumption described 
above, each group should consist of 141 patients. Further-
more, according to the same assumption, when the nonin-
feriority detection level is 8%, each group should consist of 
109 patients. For reference only, the relation of each group’s 
rate of SSI, with the assumption that the permissible differ-
ence is 5%, the power of the test is 80%, and the one sided 
signiﬁ cance level is 5%, with the supposition that the prac-
ticable number of patients is 100 or 150, is shown in Fig. 2. 
This Fig. indicates that rate of SSI in the new-treatment 
group has to be less than the SSI rate in the control group 
if the study is performed in Japan. Thus, it is necessary to 
assess the number of the patients required for each proto-
col, but, in practice, for a noninferiority study, it is desirable 
for the number of patients in each group to be at least 100. 
We used Sample Power Release 2.0, 2000, by Michael 
Borenstein, Hanna Rothstein, Jacob Cohen, David Schoen-
feld, and Jesse Berlin (SPSS, Chicago, IL, USA), to calcu-
late the number of patients required. For the implementation 
of clinical studies, clinicians are encouraged to seek advice 
from epidemiologists or statisticians.
Points to note in the preparation of protocols
When performing clinical studies of prophylactic antimicro-
bial drugs for postoperative infections, those items that 
have already been recommended on the basis of evidence 
must be given consideration. However, this rule does not 
apply if the study is designed to investigate one of these 
items.
(1) Ethically, clinical studies that compare an AMP with 
no antibiotic cover at all should not be performed for 
any operation or class of operation in which the use of 
that AMP has been shown to reduce SSI rates, based 
on evidence from clinical trials, nor should such a com-
parative study be performed for those operations after 
which an SSI would represent a catastrophe. Such 
comparative studies may be performed for clean oper-
ations2 (except for cardiovascular surgery, neurosur-
gery, and laparoscopic cholecystectomy,3,4 in which the 
incidence of SSI is extremely low.5
(2) As AMP agents to be selected as control drugs in 
comparative studies, ﬁ rst-generation and second-
generation cephems6–10 and penicillins (see “Selection 
of AMP agents” below) are recommended.
(3) Antimicrobial drugs for injection are generally used.6 
This rule does not, however, apply if the usefulness of 
antimicrobial drugs for oral use is being assessed in the 
study.
(4) When β-lactams are used as the AMP, the initial dose 
is administered within 2 h (within 30 min, if possible) 
before the operation.11,12
Fig. 1. Number of patients required for a study when the surgical-site 
infection (SSI) rates in the groups vary from 5% to 30%
Fig. 2. The relation of SSI rates in two groups, with the supposition 
that the practicable number of patients is 100 or 150
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(5) For a prolonged operation, additional AMP agents 
should be infused.13
(6) In general, single-dose prophylaxis or prophylaxis 
ending within 24 h after the operation is recommended. 
In Japan, however, AMP agents tend to be used for a 
longer duration postoperatively. Therefore, compara-
tive studies to determine the optimum duration of 
AMP use are still being performed. In such cases, 
continuing AMP for up to 4 days after the operation 
may be allowed for the longer-duration arm.14–16
(7) The intervals between administrations of β-lactams 
are decided by taking into consideration the half-life 
of the antimicrobial drug. The desirable frequency of 
administration of time-dependent antimicrobial drugs 
with a half-life of about 2 h is three times daily.17,18
(8) For clinical studies in surgery for the lower intestine, 
it is necessary to specify, in the protocols, the 
presence/absence of preoperative administration of 
nonabsorbable oral antimicrobial drugs. When oral 
antimicrobial drugs are used, they should be adminis-
tered in divided doses on the day before the operation, 
and they should be effective against aerobic gram-
negative organisms and anaerobic bacteria.19–21
(9) Perioperative management and surgical procedures 
are performed by the methods outlined in the section 
“Protocol for perioperative management and surgical 
procedures” below.
(10) When gastrointestinal operation is included in a study, 
the methods for anastomoses must be uniﬁ ed to 
mechanical anastomosis or hand-sewn anastomosis.
(11) Randomized comparative studies statistically require 
certain numbers of patients, as outlined above in the 
section “Number of patients required for a noninferi-
ority study”.
(12) The efﬁ cacy of prophylactic antimicrobial drugs is 
evaluated from the incidence of SSI. However, it is 
desirable to describe the incidence of remote infec-
tions as well.
(13) Anaerobic culture as well as aerobic culture is per-
formed for the screening of causative organisms for 
postoperative infections. This should therefore be 
kept in mind when specimens are collected.22
Clariﬁ cation of inclusion and exclusion criteria for an 
AMP clinical study
Selection of operation for an AMP clinical study
The standard surgical procedure is selected for each class 
of operation, and criteria for the evaluation of drug efﬁ cacy 
are established. Laparoscopic surgery, implant surgery, and 
organ transplantation should be dealt with differently from 
other operations. In general, an AMP is not indicated for 
an operation classiﬁ ed as “contaminated” or “dirty”. In 
such operations, patients frequently receive therapeutic 
antimicrobial agents perioperatively. However, gastroduo-
denal perforation (within 24 h after the occurrence) and 
traumatic/iatrogenic intestinal perforation (within 12 h 
after the occurrence) are included as the subjects of clinical 
studies of AMP, because the degree of bacterial conta-
mination is low, and nonperforating appendicitis, chole-
cystitis, and strangulated intestinal obstruction (ileus) are 
also included as the subjects of clinical studies of AMP, 
because the infected lesions are completely removed 
operatively.23
Exclusion criteria
(1) Patients with contaminated wounds and dirty-infected 
wounds
(2) Patients with histories of adverse events associated with 
the antimicrobial drugs used
(3) Patients with severe cardiac, hepatic, and/or renal 
dysfunction
(4) Patients treated with antimicrobial drugs within 7 days 
before the operation
(5) Patients who were judged to be inappropriate for study 
entry by the physician-in-charge
(6) When the severity of patient is included in the exclusion 
criteria, the deﬁ nition is distinctly established for each 
disease
Table 1. Primary operative procedures as the subjects of clinical evaluation of prophylactic antimicrobial drugs
Clean wound Cardiac surgery, vascular surgery, thoracic surgery, neurosurgical surgery, herniorrhaphy, breast surgery, 
 surgery of endocrine system Splenectomy
Urological surgery (the urinary tract is not opened)
Surgery on the head and neck (operative wounds are not open to the paranasal sinuses, oral cavity, or 
 pharynx)
Orthopedic surgery (e.g., amputations of the extremities, operations on the spine and hip joints)
Ophthalmological surgery
Clean-contaminated wound Gastrointestinal tract surgery: e.g., esophageal surgery, gastric surgery, small-bowel surgery, colorectal surgery, 
 hepatectomy, biliary tract surgery, pancreatic surgery (head, body, and tail; nonperforating), appendectomy
Surgery on the head and neck (operative wounds are open to the paranasal sinuses, oral cavity, and pharynx)
Obstetric-gynecological surgery: e.g., cesarean section, artiﬁ cial termination of pregnancy, vaginal and total 
 abdominal hysterectomy (excluding operations for malignant tumors)
Genitourinary surgery (the urinary tract is opened)
Respiratory surgery: e.g., pneumonectomy
 175
Selection of AMP agents
In clinical studies, those antimicrobial drugs that are con-
sidered to be the most useful in the operation, are used. 
Because intraoperative contamination with indigenous 
bacterial ﬂ ora at the site of maneuvers can cause SSI, anti-
microbial drugs with antimicrobial activity against these 
bacterial ﬂ ora are selected. Cefazolin provides adequate 
coverage for many clean and clean-contaminated opera-
tions,6 but AMP for operations on the distal intestinal tract 
mandates the use of an agent such as cefmetazole or ﬂ o-
moxef, which provides anaerobic coverage.9 In operations 
on the head and neck, ampicillin is recommended, but 
cefazolin, sulbactam/ampicillin,24 and cefmetazole can also 
be used. Piperacillin is recommended for operations on the 
biliary tract.25,26
Protocol for perioperative management and 
surgical procedures
Preoperative management
(1) When a remote infection is present before an elective 
operation, the infection should be treated and the 
elective operation postponed until the infection has 
resolved.27,28
(2) Do not remove hair preoperatively unless the hair at or 
around the incision site will interfere with the opera-
tion. When hair removal is performed, electric hair clip-
pers are to be used, and if possible, it is desirable that 
the hair removal be performed immediately before the 
operation.29
(3) Encourage cessation of tobacco use. Instruct patients to 
quit smoking for at least 30 days before an elective 
operation.30,31
(4) Perform a preoperative surgical scrub for at most 5 min. 
When using an alcohol-based surgical hand-scrub 
product with persistent activity, brushes are not used 
routinely. If brushes are used, only the nails and the 
spaces between the ﬁ ngers are washed with the 
brushes.32–35
Intraoperative management
(1) The AMP agent is re-administered intraoperatively 
during prolonged opertions.13
(2) A disinfectant is not used on the wound surface, but 
washing with a physiological saline solution is per-
formed at the time of abdominal closure.36
(3) A synthetic monoﬁ lament absorption thread is used for 
fascial suturing.
(4) When the wound is closed, operative instruments is 
exchanged for a sterilized one.
(5) If drainage is necessary, use a closed suction drain. 
Place the drain through a separate incision distant from 
the operative incision. Remove the drain as soon as 
possible.37
(6) Surgical gloves are changed a few hours after the 
start of the operation or after the completion of the 
anastomosis.
(7) Intraperitoneal washing with a saline solution is 
performed at the end of an abdominal procedure.
Postoperative management
(1) Blood sugar is maintained at less than 200 mg/dl for up 
to 48 h after the operation.38
(2) An incision that has been closed primarily is to 
be protected with a sterile dressing for 48 h 
postoperatively.39
(3) When performing wound care, standard precautions 
should be observed.33
Descriptions of patient backgrounds in 
a comparative study
In a comparative study, the following factors are described, 
to ensure that there are no signiﬁ cant differences in the 
backgrounds of any two study groups: age, sex, diseases, 
surgical procedures, duration of the operation,27,40,41 wound 
classiﬁ cation,40,42,43 American Society of Anesthesiologists 
(ASA) score,44–46 comorbidities (diabetes mellitus, chronic 
pulmonary diseases), administration of immunosuppres-
sants,47 emergency operation, implantation, laparoscopic 
operation,48 combined operation. Information in the results 
describes: SSI (deﬁ ned as superﬁ cial incisional wound infec-
tion, deep incisional wound infection, and organ/space 
infection), remote infection, mortality, side effects, toler-
ance, and isolated organisms. Results of susceptibility 
testing of isolates may also be described.
Background factors are presented in a Table to show the 
absence of intergroup differences, and intergroup evalua-
tion is performed using data from all enrolled patients. The 
United States National Nosocomial Infections Surveillance 
(NNIS) system40,41 has revealed the following elements of 
an SSI risk index; (1) wound classiﬁ cation class 3 or greater, 
(2) ASA score 3 or greater, and (3) prolonged operation (>t 
hours27). The risk index categories are scored from 0 to 3 
points according to the combination of the three risk index 
items. The incidence of SSI may also be evaluated by strati-
fying into a four-risk index category.
Acknowledgments We thank Yoshimitsu Hiejima (Tokyo Healthcare 
University) for helpful advice during the preparation of this article.
Appendix
Diagnostic criteria for SSI6
Classiﬁ cation of SSI (Fig. 3)
(1) Superﬁ cial incisional SSI involves only skin and subcu-
taneous tissue.
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(2) Deep incisional SSI involves deep soft tissue (fascia and 
muscle layers).
(3) Organ/space SSI involves any part of the body, exclud-
ing the skin incision, fascia, or muscle layers, that is 
opened or manipulated during the operative procedure: 
examples of organ/space SSI are: intraabdominal infec-
tion, endocarditis/pericarditis, mediastinitis, intracra-
nial infection, osteomyelitis, sinusitis, mastitis, vascular 
infections.
Diagnosis of SSI
SSI is deﬁ ned as an infection occurring within 30 days after 
the operative procedure, if no implant is left in place, or an 
infection occurring within 1 year if an implant (e.g., hernia 
mesh, artiﬁ cial blood vessel, artiﬁ cial joint) is in place and 
the infection appears to be related to the operative 
procedure.
Superﬁ cial incisional SSI
At least one of the following criteria is met:
(1) There is purulent drainage from the superﬁ cial 
incision.
(2) Organisms are isolated from exudates or tissue that are 
aseptically collected from the superﬁ cial incisional 
site.
(3) The incision is opened by surgeons to perform surgical 
drainage, and the drainage ﬂ uid is culture-positive or 
not cultured when the patient has at least one of the 
following symptoms or signs: pain or tenderness, local-
ized swelling, or rubor and heat sensation. A culture-
negative ﬁ nding does not meet this criterion.
(4) The diagnosis is made by the surgeon or attending 
physician.
Points to note. When resident skin ﬂ orae, which include 
Staphylococcus epidermidis and genus Corynebacterium, 
are detected, SSI is differentiated from fat necrosis with 
reference to criteria 1, 3, and 4 described above. However, 
a stitch abscess at the points of suture penetration is not 
diagnosed as SSI.
Deep incisional SSI
At least one of the following criteria is met:
(1) There is purulent drainage from the deep incision but 
not from the organ/space component of the surgical 
site.
(2) A deep incision spontaneously dehisces or is deliber-
ately opened by a surgeon and is culture-positive or not 
cultured when the patient has at least one of the follow-
ing signs or symptoms: fever (body temperature >38°C), 
localized pain, or tenderness. A culture-negative ﬁ nding 
does not meet this criterion.
(3) Abscesses or other deep incisional infections are found 
on direct examination, during reoperation, or by histo-
pathological or radiologic examination.
(4) The diagnosis of a deep incisional SSI is made by a 
surgeon or attending physician.
Points to note. A patient showing wound disruption but 
lacking distinct signs of infection, with negative results for 
bacterial detection or isolation of skin resident ﬂ ora is not 
diagnosed as having an SSI.
Organ/Space SSI
At least one of the following criteria must be met:
(1) There is purulent drainage from a drain that is placed 
through a stab wound into the organ/space.
(2) Organisms are isolated from a culture of ﬂ uid or tissue 
in the organ/space.
(3) An abscess or other evidence of infection involving the 
organ/space is found on direct examination, during 
reoperation, or by histopathological or radiologic 
examination.
(4) The diagnosis of an organ/space SSI is made by the 
surgeon or attending physician.
Points to note. Suture failure is classiﬁ ed as an organ/space 
SSI. Distinct infection at the site of drain insertion is not 
diagnosed as an SSI.
References
 1. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods 
for metaanalysis in medical research. Hoboken; John Wiley and 
Sons; 2000.
 2. Platt R, Zaleznik DF, Hopkins CC, Dellinger EP, Karchmer AW, 
Bryan CS, et al. Perioperative antibiotic prophylaxis for her-
niorrhaphy and breast surgery. N Engl J Med 1990;322:153–
60.
Fig. 3. Classiﬁ cation of SSI
 177
 3. Al-Ghnaniem R, Benjamin IS, Patel AG. Meta-analysis suggested 
antibiotic prophylaxis is not warranted in low-risk patients under-
going laparoscopic cholecystectomy. Br J Surg 2003;90:365–6.
 4. Chang WT, Lee KT, Chuang SC, Wang SN, Kuo KK, Chen JS, 
et al. The impact of prophylactic antibiotics on postoperative 
infection complication in elective laparoscopic cholecystectomy: a 
prospective randomized study. Am J Surg 2006;191:721–5.
 5. Keighley MRB, Williams NS. Sepsis and the use of antibiotic cover 
in colorectal surgery. In: Keighley MRB, Williams NS, editors. 
Surgery of the anus, rectum and colon. 2nd ed. London: WB Saun-
ders; 1999. p. 107–35.
 6. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. 
Guideline for prevention of surgical site infection, 1999. Infect 
Control Hosp Epidemiol 1999;20:247–78.
 7. Antonelli W, Borgani A, Machella C, Morri F, Parrino A, Poloni 
M, et al. Comparison of two systemic antibiotics for the prevention 
of complications in elective colorectal surgery. Ital J Surg Sci 
1985;15:255–8.
 8. Krepel CJ, Gohr CM, Edmiston CE, Condon RE. Surgical sepsis: 
constancy of antibiotic susceptibility of causative organisms. 
Surgery 1995;117:505–9.
 9. Nichols RL, Smith JW. Anaerobes from a surgical perspective. 
Clin Infect Dis 1994;18:S280–6.
10. Song F, Glenny AM. Antimicrobial prophylaxis in colorectal 
surgery: a systematic review of randomized controlled trials. Br J 
Surg 1998;85:1232–41.
11. Classen DC, Evance RS, Pestonik SL, Horn SD, Menlove RL, 
Burke JP. The timing of prophylactic administration of antibiotics 
and the risk of surgical wound infection. N Engl J Med 1992;
326:281–6.
12. Burk JF. The effective period of preventive antibiotic action in 
experimental incisions and dermal lesions. Surgery 1961;50:
161–8.
13. Ohge H, Takesue Y, Yokoyama T, Murakami Y, Hiyama E, 
Yokoyama Y, et al. An additional dose of cefazolin for intraopera-
tive prophylaxis. Surg Today 1999;29:1233–6.
14. Takesue Y, Yokoyama T, Akagi S, Ohge H, Imamura Y, Murakami 
Y, et al. Changes in the intestinal ﬂ ora after the administration of 
prophylactic antibiotics to patients undergoing a gastrectomy. Surg 
Today 2002;32:581–6.
15. Harbarth S, Samore MH, Lichtenberg D, Carmeli Y. Prolonged 
antibiotic prophylaxis after cardiovascular surgery and its effect on 
surgical site infections and antimicrobial resistance. Circulation 
2000;101:2916–21.
16. DiPiro JT, Cheung RP, Bowden TA Jr, Mansberger JA. Single 
dose systemic antibiotic prophylaxis of surgical wound infections. 
Am J Surg 1986;152:552–9.
17. Craig WA. Pharmacokinetic/pharmacodynamic parameter: ratio-
nale for antibacterial dosing of mice and men. Clin Infect Dis 
1998;26:1–10.
18. Craig WA. Interrelationship between pharmacokinetics and phar-
macodynamics in determining dosage regimens for broad-spec-
trum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89–96.
19. Polacek MA, Sanfelippo P. Oral antibiotic bowel preparation and 
complication in colon surgery. Arch Surg 1968;97:412–8.
20. Takesue Y, Yokoyama T, Akagi S, Ohge H, Murakami Y, Sakashita 
Y, et al. A brief course of colon preparation with oral antibiotics. 
Surg Today 2000;30:112–6.
21. Zmora O, Pikarsky AJ, Wexner SD. Bowel preparation for 
colorectal surgery. Dis Colon Rectum 2001;44:1537–49.
22. Finegold SM. Perspective on susceptibility testing of anaerobic 
bacteria. Clin Infect Dis 1997;25(Suppl 2):S251–3.
23. Mazuski JE, Sawyer RG, Nathens AB, DiPiro JT, Schein M, 
Kudsk KA, et al. The Surgical Infection Society Guidelines on 
antimicrobial therapy for intra-abdominal infections: an executive 
summary. Surg Infect 2002;3:161–73.
24. Seven H, Savin I, Jurgut S. Antibiotic prophylaxis in clean neck 
dissections. J Laryngol Otol 2004;118:213–6.
25. Aloj G, Bianco C, Covelli I, Blenkharn JI, Blumgart LH, Benjamin 
IS. Antibiotic prophylaxis for biliary tract surgery: selection of 
patient and agent. Int Surg 1991;76:131–4.
26. Lipsett PA, Pitt HA. Acute cholangitis. Front Biosci 2003;8:
s1229–39.
27. Garibaldi RA, Cushing D, Lerer T. Risk factors for preoperative 
infection. Am J Med 1991;91(Suppl 3B):158S–63S.
28. Lee JT. Operative complications and quality improvement. Am J 
Surg 1996;171:545–7.
29. Alexander JW, Fisher JF, Boyajian M, Palmquist J, Morris MJ. 
The inﬂ uence of hair-removal methods on wound infections. Arch 
Surg 1983;118:347–52.
30. Nagachinta T, Stephens M, Reitz B, Polk BF. Risk factors for sur-
gical wound infection following cardiac surgey. J Infect Dis 
1987;156:967–73.
31. Jones JK, Triplett RG. The relationship of cigarette smoking to 
impaired intraoral wound healing: a review of evidence and impli-
cations for patient care. J Oral Maxillofac Surg 1992;50:237–9.
32. Parienti JJ, Thibon P, Heller R, Le Roux Y, von Theobald P, 
Bensadoun H, et al. Hand-rubbing with an aqueous alcoholic solu-
tion vs traditional surgical hand-scrubbing and 30-day surgical site 
infection rates: a randomized equivalence study. JAMA 2002;
288:722–7.
33. Gerberding JL. Guideline for hand hygiene in health-care setting.
MMWR Morb Martal Wkly Rep 2002;51:1–45.
34. Pereira LJ, Lee GM, Wade KJ. An evaluation of ﬁ  ve protocols 
for surgical handwashing in relation to skin condition and micro-
bial counts. J Hosp Infect 1997;36:49–65.
35. Hobson DW, Woller W, Anderson L, Guthery E. Development 
and evaluation of a new alcohol-based surgical hand scrub formu-
lation with persistent antimicrobial characteristics and brushless 
application. Am J Infect Control 1998;26:507–12.
36. Cervantes-Sanchez CR, Gutierrez-Vega R, Vazquez-Carpizo JA. 
Syringe pressure irrigation of subdermic tissue after appendectomy 
to decrease the incidence of postoperative wound infection. World 
J Surg 2000;24:38–42.
37. Sarr MG, Parikh KJ, Minken SL, Zuidema GD, Cameron JL. 
Closed-suction versus Penrose drainage after cholecystectomy. A 
prospective, randomized evaluation. Am J Surg 1987;153:394–98.
38. Latham R, Lancaster AD, Covington JF, Pirolo JS, Thomas CS. 
The association of diabetes and glucose control with surgical-site 
infections among cardiothoracic surgery patients. Infect Control 
Hosp Epidemiol 2001;22:607–12.
39. Chrintz H, Vibits H, Cordtz TO, Harreby JS, Waaddegaard P, 
Larsen SO. Need for surgical wound dressing. Br J Surg 1989;
76:204–5.
40. Claesson BEB, Holmlund DEW. Predictors of intraoperative 
bacterial contamination and postoperative infection in elective 
colorectal surgery. J Hosp Infect 1988;11:127–35.
41. Culver DH, Horan TC, Gaynes RP, Martone WJ, Jarvis WR, 
Emori TG, et al. Surgical wound infection rates by wound class, 
operative procedure, and patient risk index. Am J Med 1991;
91(Suppl 3B):152S–7S.
42. Gaynes RP, Culver DH, Horan TC, Edwards JR, Richards C, 
Tolson JS. Surgical site infection (SSI) rates in the United States, 
1992–1998: The National Nosocomial Infections Surveillance 
System basic SSI risk index. Clin Infect Dis 2001;33(Suppl 2):
S69–S77.
43. Sawyer RG, Pruett TL. Wound infections. Surg Clin North Am 
1994;74:519–36.
44. Owens WD, Felts JA, Spitznagel EL. ASA physical status classiﬁ -
cations: a study of consistency of rating. Anesthesiology 1978;49:
239–43.
45. Haynes SR, Lawler PGP. An assessment of consistency of ASA 
physical status classiﬁ  cation allocation. Anaesthesia 1995;50:
195–9.
46. Salemi C, Anderson D, Flores D. American Society of Anesthesi-
ology scoring discrepancies affecting the National Nosocomial 
Infection Surveillance System: surgical-site-infection risk index 
rates. Infect Control Hosp Epidemiol 1997;18:246–7.
47. Haley RW, Culver DH, Morgan WM, White JW, Emori TG, 
Hooton TM. Identifying patients at high risk of surgical wound 
infection: a simple multivariate index of patient susceptibility and 
wound contamination. Am J Epidemiol 1985;121:206–15.
48. Richards C, Edwards J, Culver D, Emori TG, Tolson J, Gaynes R, 
et al. Does using a laparoscopic approach to cholecystectomy 
decrease the risk of surgical site infection? Ann Surg 2003;237:
358–62.
